Cost-Effectiveness

• This 1993 analysis calculated that EPO treatment for anemia in dialysis patients was more than 570 times more expensive per quality-adjusted life year (QALY) gained as compared with cholesterol testing and treatment by diet in adults

• However, future cost-utility analysis needs to take into consideration significant decreases in mortality shown with EPO when hematocrits of 33-36% are achieved

Previous slide

Next slide

Back to first slide

View graphic version

Robinson, Ray. Economic Evaluation and Health Care: Cost-Utility Analysis. [Miscellaneous Article] BMJ. 307(6908):859-862, October 2, 1993.